Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Core One Labs Inc. C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan... see more

Recent & Breaking News (CSE:COOL)

Core One Labs' Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT

Accesswire September 2, 2022

Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin

Accesswire September 1, 2022

Core One Labs Engages in Talks With GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic Psilocybin

Accesswire August 26, 2022

Core One Labs' Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies

Accesswire August 19, 2022

Core One Labs' Akome Achieves Significant Research Milestone with Positive Neurogenesis Stimulation Studies Results

Accesswire August 18, 2022

Core One Labs (CSE:COOL) subsidiary Vocan successfully converts Psilocin precursor into Psilocybin

John Ballem  August 16, 2022

Core One Labs' Vocan Successfully Converts Psilocin Precursor into Psilocybin

Accesswire August 16, 2022

Core One Labs' Upgrades to OTCQB Venture Market

GlobeNewswire April 6, 2022

Core One Labs' Akome Receives Positive Results from Bioassay Studies

GlobeNewswire April 2, 2022

Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities

GlobeNewswire March 19, 2022

Core One's Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan's Mass Production Capabilities

GlobeNewswire March 15, 2022

Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin

GlobeNewswire March 12, 2022

Core One Labs' Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations

GlobeNewswire March 4, 2022

Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)

GlobeNewswire March 3, 2022

Vancouver discovery will make 'Magic Mushroom' mental health care cheaper

GlobeNewswire February 23, 2022

Core One Labs' (CSE:COOL) files patent for its recombinant production system

Brieanna McCutcheon  February 22, 2022

Core One Labs' Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)

GlobeNewswire February 21, 2022

Core One Labs (CSE:COOL) acquires Awakened Biosciences and its patents

Caroline Egan  February 11, 2022

Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents

GlobeNewswire February 11, 2022

Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

GlobeNewswire February 10, 2022